10.1038/s41422-020-0384-8 51 MaJ.ShiM.ZhangX.LiuX.ChenJ.ZhangR.et al (2018)
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Weight Loss GLP-1 Injections for Weight Loss The Glorious Glow Experience Personalized Care A treatment plan tailored to your goals and skin
Additionally, it may be helpful to have note cards written in the local language to communicate that the person has type 1 diabetes and may need urgent glucose administration if hypoglycaemic
Youll see a board-certified rheumatologist in days, not months, via telehealth across 20+ states with no referral required
Im using it. If you're already on Ozempic or Wegovy and wondering how to adjust your training as the weight comes off, read our guide on how to adjust your workouts on Ozempic or Wegovy
